tert-Butyl (2-(S-methylsulfonimidoyl)ethyl)carbamate | 2241129-31-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 英文名称: tert-Butyl (2-(S-methylsulfonimidoyl)ethyl)carbamate
• 英文别名: tert-butyl N-[2-(methylsulfonimidoyl)ethyl]carbamate
• CAS: 2241129-31-5
• 化学式: C₈H₁₈N₂O₃S
• 分子量: 222.31
• InChiKey: GBBXHNSJKIYNEC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  87.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• BIARYL DERIVATIVE, PREPARATION METHOD THEREOF AND PHARMACEUTICAL APPLICATION THEREOF
  申请人：Abbisko Therapeutics Co., Ltd.

  公开号：EP3750887A1

  公开（公告）日：2020-12-16

  Disclosed are a biaryl derivative having a structure represented by Formula (I) and inhibitory activity against PD-1/PD-L1 interaction, a preparation method thereof, and a pharmaceutical application thereof. The series of compounds of the present invention can be widely applied to the preparation of a medicament for preventing and/or treating cancer or tumors, immune-related diseases and disorders, contagious diseases, infectious diseases or metabolic diseases that are mediated by a PD-1/PD-L1 signaling pathway, and shows promise for the development of a new generation of PD-1/PD-L1 inhibitors.

  本发明公开了一种具有式(I)代表的结构和对PD-1/PD-L1相互作用具有抑制活性的双芳基衍生物、其制备方法及其药物应用。本发明的系列化合物可广泛应用于制备预防和/或治疗由 PD-1/PD-L1 信号通路介导的癌症或肿瘤、免疫相关疾病和紊乱、传染性疾病、感染性疾病或代谢性疾病的药物，并有望开发出新一代 PD-1/PD-L1 抑制剂。
• Substituted sulfoximine compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10927086B2

  公开（公告）日：2021-02-23

  Compounds of Formula I, or a pharmaceutically acceptable salt, solvate or hydrate thereof: (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

  式 I 的化合物或其药学上可接受的盐、溶液或水合物：(I).本文还公开了本文公开的化合物在潜在治疗或预防 IDO 相关疾病或紊乱中的用途。本文还公开了包含本文公开的化合物的组合物。本文进一步公开了这些组合物在潜在治疗或预防 IDO 相关疾病或紊乱中的用途。
• [EN] BIARYL DERIVATIVE, PREPARATION METHOD THEREOF AND PHARMACEUTICAL APPLICATION THEREOF<br/>[FR] DÉRIVÉ DE BIARYLE, SON PROCÉDÉ DE PRÉPARATION, ET SON APPLICATION PHARMACEUTIQUE<br/>[ZH] 一种联芳基衍生物、其制备方法和在药学上的应用
  申请人：ABBISKO THERAPEUTICS CO LTD

  公开号：WO2019149183A1

  公开（公告）日：2019-08-08

  本发明涉及一种式(Ⅰ)结构具有对PD-1/PD-L1相互作用有抑制活性的联芳基衍生物、其制备方法和在药学上的应用。本发明系列化合物可广泛应用于制备预防和/或治疗由PD-1/PD-L1信号通路介导的癌症或肿瘤、免疫相关疾病及紊乱、传染性疾病、感染性疾病或代谢性疾病的药物,有望开发成新一代PD-1/PD-L1抑制剂。
• NOVEL SUBSTITUTED SULFOXIMINE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP3585774B1

  公开（公告）日：2021-11-10